EXELIXIS, INC. (NASDAQ:EXEL) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 of the Original Filing to disclose at the end of that item Exelixis' decision regarding how frequently it will conduct future stockholder advisory votes on executive compensation. No other changes have been made to the Original Filing.
Item 5.07. Submission of Matters to a Vote of Security Holders.
Exelixis held its Annual Meeting of Stockholders (the "Annual Meeting") on May24, 2017, at its offices located at 210 East Grand Avenue, South San Francisco, CA 94080.
The voting results of the matters presented at the Annual Meeting are as follows:
|
1. |
The election of each of Michael M. Morrissey, Ph.D., Stelios Papadopoulos, Ph.D., George A. Scangos, Ph.D. and Lance Willsey, M.D. as directors of Exelixis until the 2020 annual meeting of stockholders, and until his successor is elected and qualified, or until his earlier death, resignation or removal, was approved as follows: |
|
FOR |
AGAINST |
ABSTAIN |
BROKER NON-VOTES |
|
|
Michael M. Morrissey, Ph.D. |
189,126,322 |
503,107 |
895,899 |
53,945,960 |
|
Stelios Papadopoulos, Ph.D. |
179,468,438 |
10,128,913 |
927,977 |
53,945,960 |
|
George A. Scangos, Ph.D. |
180,990,866 |
8,552,190 |
982,272 |
53,945,960 |
|
Lance Willsey, M.D. |
181,061,435 |
8,534,011 |
929,882 |
53,945,960 |
Exelixis’ Class I directors, Charles Cohen, Ph.D., George Poste, D.V.M., Ph.D., FRS, and Jack L. Wyszomierski will each continue to serve on the Board of Directors until the 2018 annual meeting of stockholders and until his successor is elected and qualified, or until his earlier death, resignation or removal. Exelixis’ Class II directors, Carl B. Feldbaum, Esq., Alan M. Garber, M.D., Ph.D., Vincent T. Marchesi, M.D., Ph.D. and Julie Anne Smith, will each continue to serve on the Board of Directors until the 2019 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier death, resignation or removal.
|
2. |
The ratification of Ernst& Young LLP as the Exelixis independent registered public accounting firm for the fiscal year ending December 29, 2017, was approved as follows: |
|
FOR |
AGAINST |
ABSTAIN |
BROKER NON-VOTES |
|
243,001,537 |
766,401 |
703,350 |
|
3. |
The 2017 Plan was approved as follows: |
|
FOR |
AGAINST |
ABSTAIN |
BROKER NON-VOTES |
|
137,568,045 |
49,721,622 |
3,235,661 |
53,945,960 |
|
4. |
The compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement, received advisory approval as follows: |
|
FOR |
AGAINST |
ABSTAIN |
BROKER NON-VOTES |
|
184,930,909 |
2,298,135 |
3,296,284 |
53,945,960 |
|
5. |
The preferred frequency of stockholder advisory votes on the compensation of Exelixis' named executive officers, received advisory approval for one year as follows: |
|
ONE YEAR |
TWO YEARS |
THREE YEARS |
ABSTAIN |
BROKER NON-VOTES |
|
174,122,554 |
470,428 |
15,751,371 |
180,975 |
53,945,960 |
In accordance with the Board of Directors recommendation as set forth in Exelixis' proxy statement for the Annual Meeting and consistent with the stated preference of Exelixis' stockholders as reflected above, on September 7, 2017, Exelixis determined that future stockholder advisory votes on executive compensation will be conducted on an annual basis, until the next stockholder advisory vote on this matter is held. Exelixis is required to hold votes on such frequency every six years.
About EXELIXIS, INC. (NASDAQ:EXEL)
Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins. EXELIXIS, INC. (NASDAQ:EXEL) Recent Trading Information
EXELIXIS, INC. (NASDAQ:EXEL) closed its last trading session up +0.31 at 25.97 with 4,567,016 shares trading hands.
